Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 95-102

  Shen, Fei ^a   Chu, Shaoyou ^b,d   Bence, Aimee K ^a   Bailey, Barbara ^a   Xue, Xinjian ^a   Erickson, Priscilla A ^a   Montrose, Marshall H ^b,e   Beck, William T ^c   Erickson, Leonard C ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIRICODAR; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; MEMBRANE PROTEIN; ONT 093; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; GENE; IN VITRO STUDY; IN VIVO STUDY; MDR1 GENE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ASSAY; WILD TYPE; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOSPORINE; CYCLOSPORINS; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; VERAPAMIL;

EID: 37349069575     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127704     Document Type: Article

References (29)

1. Bouhadir KH, Alsberg E, and Mooney DJ (2001) Hydrogels for combination delivery of antineoplastic agents. Biomaterials 22:2625-2633.
2. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
3. Broxterman HJ, Giaccone G, and Lankelma J (1995) Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol 7:532-540.
4. Cutts SM, Swift LP, Rephaeli A, Nudelman A, and Phillips DR (2003) Sequence specificity of adriamycin-DNA adducts in human tumor cells. Mol Cancer Ther 2:661-670.
5. De Beer EL, Bottone AE, and Voest EE (2001) Doxorubicin and mechanical performance of cardiac trabeculae after acute and chronic treatment: a review. Eur J Pharmacol 415:1-11.
6. Diestra JE, Condom E, Del Muro XG, Scheffer GL, Perez J, Zurita AJ, Munoz-Segui J, Vigues F, Scheper RJ, Capella G, et al. (2003) Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol 170:1383-1387.
7. Doll RJ, Kirschmeier P, and Bishop WR (2004) Farnesyltransferase inhibitors as anticancer agents: critical crossroads. Curr Opin Drug Discov Dev 7:478-486.
8. Ellison G, Klinowska T, Westwood RFR, Docter E, French T, and Fox JC (2002) Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 55:294-299.
9. Ferry DR, Traunecker H, and Kerr DJ (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur J Cancer 32A:1070-1081.
10. Gerrard G, Payne E, Baker RJ, Jones DT, Potter M, Prentice HG, Ethell M, McCullough H, Burgess M, Mehta AB, et al. (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89:782-790.
11. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58.
12. Hermanussen S, Do M, and Cabot PJ (2004) Reduction of beta-endorphin-containing immune cells in inflamed paw tissue corresponds with a reduction in immune-derived antinociception: reversible by donor activated lymphocytes. Anesth Analg 98:723-729.
13. Jabbour E, Kantarjian H, and Cortes J (2004) Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma 45:2187-2195.
14. Keller RP, Altermatt HJ, Nooter K, Poschmann G, Laissue JA, Bollinger P, and Hiestand PC (1992) SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int J Cancer 50:593-597.
15. Leonessa F and Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43-73.
16. Meschini S, Molinari A, Calcabrini A, Citro G, and Arancia G (1994) Intracellular localization of the antitumour drug adriamycin in living cultured cells: a confocal microscopy study. J Microsc 176:204-210.
17. Molinari A, Calcabrini A, Crateri P, and Arancia G (1990) Interaction of anthracyclinic antibiotics with cytoskeletal components of cultured carcinoma cells (CG5). Exp Mol Pathol 53:11-33.
18. Oza AM (2002) Clinical development of P glycoprotein modulators in oncology. Novartis Found Symp 243:103-115; discussion 115-108.
19. Pincheira R, Chen Q, and Zhang JT (2001) Identification of a 170-kDa protein over-expressed in lung cancers. Br J Cancer 84:1520-1527.
20. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, et al. (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682-691.
21. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, and Baer MR (2005) Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11:2320-2326.
22. Rahman A, Treat J, Roh JK, Potkul LA, Alvord WG, Forst D, and Woolley PV (1990) A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8:1093-1100.
23. Rao US and Scarborough GA (1994) Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. Mol Pharmacol 45:773-776.
24. Rowinsky EK, Smith L, Wang YM, Chaturvedi P, Villalona M, Campbell E, Aylesworth C, Eckhardt SG, Hammond L, Kraynak M, et al. (1998) Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol 16:2964-2976.
25. Sharma R, Awasthi YC, Yang Y, Sharma A, Singhal SS, and Awasthi S (2003) Energy dependent transport of xenobiotics and its relevance to multidrug resistance. Curr Cancer Drug Targets 3:89-107.
26. Tan B, Piwnica-Worms D, and Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450-458.
27. Teodori E, Dei S, Martelli C, Scapecchi S, and Gualtieri F (2006) The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 7:893-909.
28. Thomas H and Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10:159-165.
29. Tsuruo T, Iida H, Hori K, Tsukagoshi S, and Sakurai Y (1981) Membrane affinity and metabolism of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine into cultured KB cells. Cancer Res 41:4484-4488.